Janice Lin, MD
Rheumatology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Offices
- 3
Offices
3 locations · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Community Hospital of the Monterey Peninsula · Stanford Health Care · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Lin’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A139485 · Current
Licensed to practise in California · since 2015 · expires 2027-05-31 · Tufts University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
3 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Community Hospital of the Monterey PeninsulaMonterey, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Montage HealthPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — CMS Medicare PSI 90: Patient safety and adverse events composite: 1.48 (1.22 to 1.74), Jul 2022 – Jun 2024Worse than the national rate — Postoperative acute kidney injury requiring dialysis rate: 3.12 (1.69 to 4.56) · 1,095 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative respiratory failure rate: 19.24 (14.17 to 24.3) · 1,118 cases, Jul 2022 – Jun 2024Worse than the national rate — Postoperative sepsis rate: 9.62 (6.42 to 12.82) · 1,086 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.39, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Community Hospital of the Monterey Peninsula
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 5 the same, 1 worse of 7 measures. Readmissions: 0 better, 11 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.48 (1.22 to 1.74) | Worse | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 3.12 (1.69 to 4.56) · 1,095 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 19.24 (14.17 to 24.3) · 1,118 cases | Worse | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 9.62 (6.42 to 12.82) · 1,086 cases | Worse | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.39 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.27 (0.39 to 2.16) · 1,873 cases | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 158.2 (110.65 to 205.75) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.3 · 74 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 135 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 184 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.7 · 686 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.4 · 1,072 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8 · 328 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.8 · 3,300 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.29 (0.11 to 0.48) · 10,234 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.1 to 0.46) · 10,572 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.25 (1.47 to 5.04) · 2,617 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.37 (1.04 to 3.7) · 2,519 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.21 (0.75 to 3.66) · 744 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.61 (0.06 to 1.17) · 8,715 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 5.2 · 156 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.28 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.799 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.732 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.7 · 152 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 625 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 6.3 · 193 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.2 · 749 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7 · 1,074 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 850 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4 (2.7 to 5.8) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.5 (10.4 to 17.4) · 224 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 153 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11.5 · 49 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.2 (10.9 to 18.6) · 711 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (1 to 1.5) · 746 cases | No different | Jan 2024 – Dec 2024 |
What patients said (520 patients answered, 28% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 5 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 62% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 84% |
| Doctors "always" explained things so they could understand | 75% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 89% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 79% |
| Nurses "always" explained things so they could understand | 79% |
| Nurses "always" listened carefully | 77% |
| Nurses "always" treated them with courtesy and respect | 89% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$40,137
Medicare paid this office $40,137 for 151 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 70 | $12,557 | $108 |
| Long return visit (40+ min) | 37 | $10,218 | $160 |
| Return visit (30+ min) | 32 | $4,223 | $78 |
| Long return visit (40+ min) | 14 | $2,220 | $117 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 66 | $2,001 | $15 |
See all 6 services
| Return visit (30+ min) | 70 | $12,557 | $108 |
| Long return visit (40+ min) | 37 | $10,218 | $160 |
| Return visit (30+ min) | 32 | $4,223 | $78 |
| Long return visit (40+ min) | 14 | $2,220 | $117 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 66 | $2,001 | $15 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 30 | $809 | $15 |
Who their Medicare patients are
151 Original Medicare patients in 2024. Average age 69 · Women 76% · Also on Medicaid 28% · Health risk score 1.86. Sicker patients than 9 in 10 peers; the typical rheumatology clinician is at 1.38.
Conditions among them: High blood pressure 62% · Depression 31% · Diabetes 30% · Chronic kidney disease 28% · Coronary heart disease 25% · Atrial fibrillation 23% · Heart failure 18% · Cancer 15% · COPD 13% · Stroke 7%.
The office billed $201,914, Medicare allowed $53,804 and paid $40,137; for 524 services of 15 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 151 | 524 | 69 | 1.86 | $201,914 | $40,137 |
| 2023 | 142 | 299 | 68 | 2.04 | $173,665 | $29,145 |
| 2022 | 166 | 362 | 68 | 1.82 | $239,562 | $35,404 |
| 2021 | 153 | 348 | 67 | 1.67 | $222,043 | $35,990 |
| 2020 | 136 | 300 | 67 | 1.95 | $145,892 | $24,233 |
| 2019 | 120 | 272 | 67 | 2.22 | $36,687 | $21,763 |
| 2018 | 137 | 297 | 66 | 1.88 | $47,698 | $24,430 |
| 2017 | 103 | 203 | 63 | 2.10 | $45,966 | $16,612 |
| 2016 | 76 | 192 | 66 | 1.73 | $54,476 | $17,717 |
| 2015 | 85 | 218 | 68 | 1.93 | $72,132 | $14,719 |
| 2014 | 54 | 83 | 70 | 1.64 | $30,990 | $5,931 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Return visit (30+ min) | 84 | $12,180 | $83 |
| Long return visit (40+ min) | 26 | $5,319 | $130 |
| Long return visit (40+ min) | 15 | $3,765 | $121 |
| Return visit (30+ min) | 11 | $1,620 | $81 |
2022: 6 services
| Return visit (30+ min) | 87 | $11,990 | $77 |
| Long return visit (40+ min) | 51 | $10,916 | $130 |
| Long return visit (40+ min) | 12 | $3,693 | $119 |
| New patient visit (60+ min) | 14 | $2,251 | $161 |
| New patient visit (45+ min) | 14 | $1,433 | $102 |
| Return visit (30+ min) | 14 | $1,282 | $67 |
2021: 6 services
| Return visit (30+ min) | 77 | $12,324 | $90 |
| Long return visit (40+ min) | 30 | $7,554 | $126 |
| Long return visit (40+ min) | 15 | $5,054 | $130 |
| New patient visit (45+ min) | 18 | $2,401 | $133 |
| Return visit (30+ min) | 12 | $1,370 | $86 |
| Telephone, internet, or electronic health record assessment and management with written report by consulting physician, at least 5 minutes | 12 | $364 | $30 |
2020: 6 services
| Return visit (30+ min) | 75 | $8,086 | $67 |
| Long return visit (40+ min) | 13 | $2,714 | $104 |
| Long return visit (40+ min) | 11 | $2,095 | $100 |
| Return visit (30+ min) | 19 | $2,077 | $67 |
| New patient visit (45+ min) | 12 | $1,386 | $116 |
| Telephone medical discussion with physician, 21-30 minutes | 13 | $1,349 | $75 |
2019: 5 services
| Return visit (30+ min) | 73 | $7,563 | $66 |
| Long return visit (40+ min) | 26 | $4,846 | $101 |
| Long return visit (40+ min) | 14 | $2,503 | $96 |
| New patient visit (45+ min) | 19 | $2,022 | $106 |
| Return visit (30+ min) | 17 | $1,806 | $65 |
2018: 5 services
| Return visit (30+ min) | 60 | $5,954 | $65 |
| Long return visit (40+ min) | 39 | $5,434 | $97 |
| Long return visit (40+ min) | 15 | $3,563 | $96 |
| New patient visit (45+ min) | 30 | $2,976 | $99 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $2,026 | $65 |
2017: 4 services
| Long return visit (40+ min) | 29 | $4,022 | $98 |
| Return visit (30+ min) | 40 | $3,880 | $69 |
| Long return visit (40+ min) | 14 | $2,319 | $93 |
| New patient visit (45+ min) | 16 | $1,848 | $116 |
2016: 5 services
| Long return visit (40+ min) | 21 | $3,369 | $99 |
| Return visit (30+ min) | 26 | $3,222 | $70 |
| New patient visit (60+ min) | 19 | $2,771 | $146 |
| Long return visit (40+ min) | 12 | $2,547 | $98 |
| New patient visit (45+ min) | 23 | $2,361 | $103 |
2015: 4 services
| Return visit (30+ min) | 40 | $5,361 | $62 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,588 | $106 |
| Long return visit (40+ min) | 14 | $1,553 | $91 |
| Short return visit (20+ min) | 21 | $870 | $33 |
2014: 1 service
| Return visit (30+ min) | 28 | $2,339 | $60 |
Medicaid work
$1,399 in 2024
Medicaid paid $1,399 for 14 billed services this clinician did in 2024, up to 14 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 14 | $1,399 |
| 2024 | 14 | 1 | 14 | $1,399 |
| 2023 | 73 | 1 | 17 | $3,092 |
| 2022 | 70 | 2 | 16 | $2,474 |
| 2021 | 66 | 1 | 14 | $2,830 |
| 2020 | 16 | 1 | 16 | $807 |
| 2019 | 69 | 1 | 16 | $2,934 |
| 2018 | 28 | 2 | 14 | $1,080 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 73 | $3,092 |
2022
| Return visit (30+ min) | 58 | $2,143 |
| Long return visit (40+ min) | 12 | $331 |
2021
| Return visit (30+ min) | 66 | $2,830 |
2020
| Return visit (30+ min) | 16 | $807 |
2019
| Return visit (30+ min) | 69 | $2,934 |
2018
| Long return visit (40+ min) | 14 | $558 |
| Return visit (30+ min) | 14 | $522 |
Drugs they prescribed that Part D paid
$1,017,297
Pharmacies billed $1,017,297 in 2024. Most of that is one immune-globulin drugs at about $9,000 a fill for a small number of people.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (13 of 671) in 2024. At or below the middle of the specialty; the typical rheumatology clinician is at 3%.
535 generic and fewer than 11 brand-name prescriptions · $1,017,297 in drug cost · 11 antibiotic prescriptions.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Octagam | Immune globulin | 33 | $301,969 | $9,151 |
| Rinvoq | None | 13 | $105,461 | $8,112 |
| Mycophenolate Mofetil | None | 31 | $9,645 | $311 |
| Hydroxychloroquine Sulfate | None | 114 | $4,057 | $36 |
| Colchicine | None | 28 | $1,975 | $71 |
See all 15 drugs
| Octagam | Immune globulin | 33 | $301,969 | $9,151 |
| Rinvoq | None | 13 | $105,461 | $8,112 |
| Mycophenolate Mofetil | None | 31 | $9,645 | $311 |
| Hydroxychloroquine Sulfate | None | 114 | $4,057 | $36 |
| Colchicine | None | 28 | $1,975 | $71 |
| Prednisone | None | 98 | $1,240 | $13 |
| Leflunomide | None | 39 | $1,127 | $29 |
| Azathioprine | None | 25 | $722 | $29 |
| Methotrexate | None | 34 | $713 | $21 |
| Methylprednisolone | None | 15 | $431 | $29 |
| Celecoxib | None | 13 | $311 | $24 |
| Allopurinol | None | 21 | $303 | $14 |
| Sulfasalazine Dr | None | 12 | $201 | $17 |
| Tramadol | None | 12 | $46 | $4 |
| Meloxicam | None | 24 | $41 | $2 |
Year by year
| 2024 | 671 | 98 | 2% (13) | None | $1,017,297 |
| 2023 | 629 | 94 | 3% (20) | None | $790,462 |
| 2022 | 697 | 94 | 2% (15) | None | $845,626 |
| 2021 | 761 | 91 | 4% (30) | None | $958,752 |
| 2020 | 993 | 93 | 5% (48) | None | $959,092 |
| 2019 | 835 | 98 | 2% (16) | None | $727,938 |
| 2018 | 713 | 138 | 3% (20) | None | $509,739 |
| 2017 | 286 | 82 | None | None | $149,342 |
| 2016 | 290 | 49 | None | None | $62,154 |
| 2015 | 265 | 33 | None | 30% | $131,895 |
| 2014 | 120 | 49 | 0% (0) | 25% | $23,080 |
| 2013 | 242 | 40 | None | 19% | $36,876 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Taltz | 18 | $135,115 | $7,506 |
| Rinvoq | 14 | $134,701 | $9,622 |
| Xeljanz | 13 | $71,801 | $5,523 |
| Mycophenolate Mofetil | 26 | $7,354 | $283 |
| Hydroxychloroquine Sulfate | 109 | $5,661 | $52 |
| Cevimeline | 14 | $2,559 | $183 |
| Colchicine | 22 | $1,738 | $79 |
| Leflunomide | 36 | $1,499 | $42 |
| Prednisone | 98 | $1,214 | $12 |
| Methotrexate | 33 | $1,057 | $32 |
| Diclofenac | 18 | $456 | $25 |
| Allopurinol | 21 | $428 | $20 |
| Meloxicam | 12 | $363 | $30 |
| Celecoxib | 15 | $342 | $23 |
| Tramadol | 20 | $130 | $6 |
2022: 21 drugs
| Rinvoq | 22 | $131,375 | $5,972 |
| Benlysta | 27 | $128,546 | $4,761 |
| Xeljanz | 19 | $106,585 | $5,610 |
| Humira | 14 | $96,720 | $6,909 |
| Orencia Clickject | 13 | $70,378 | $5,414 |
| Actemra Actpen | 27 | $45,391 | $1,681 |
| Hydroxychloroquine Sulfate | 100 | $5,294 | $53 |
| Sildenafil Citrate | 15 | $4,615 | $308 |
| Leflunomide | 19 | $1,653 | $87 |
| Cevimeline | 11 | $1,407 | $128 |
| Prednisone | 100 | $1,295 | $13 |
| Diclofenac | 38 | $1,120 | $29 |
| Methotrexate | 36 | $1,068 | $30 |
| Colchicine | 11 | $1,039 | $94 |
| Methylprednisolone | 14 | $1,022 | $73 |
| Mycophenolate Mofetil | 20 | $960 | $48 |
| Sulfasalazine Dr | 12 | $266 | $22 |
| Cyclobenzaprine | 15 | $152 | $10 |
| Amlodipine Besylate | 12 | $147 | $12 |
| Alendronate | 14 | $138 | $10 |
| Tramadol | 15 | $60 | $4 |
2021: 19 drugs
| Xeljanz | 45 | $259,677 | $5,771 |
| Benlysta | 26 | $119,293 | $4,588 |
| Xeljanz Xr | 16 | $80,794 | $5,050 |
| Actemra Actpen | 21 | $53,889 | $2,566 |
| Rasuvo | 12 | $6,304 | $525 |
| Hydroxychloroquine Sulfate | 110 | $5,837 | $53 |
| Mycophenolate Mofetil | 24 | $1,804 | $75 |
| Leflunomide | 22 | $1,720 | $78 |
| Colchicine | 18 | $1,634 | $91 |
| Cevimeline | 12 | $1,324 | $110 |
| Methotrexate | 42 | $1,159 | $28 |
| Prednisone | 90 | $1,153 | $13 |
| Diclofenac | 37 | $858 | $23 |
| Methylprednisolone | 16 | $843 | $53 |
| Sildenafil Citrate | 15 | $838 | $56 |
| Allopurinol | 11 | $234 | $21 |
| Tramadol | 30 | $71 | $2 |
| Meloxicam | 21 | $63 | $3 |
| Buspirone | 11 | $15 | $1 |
2020: 27 drugs
| Xeljanz | None | 48 | $231,333 | $4,819 |
| Gamunex-C | Immune globulin | 11 | $113,777 | $10,343 |
| Actemra | None | 31 | $106,015 | $3,420 |
| Benlysta | None | 18 | $69,812 | $3,878 |
| Orencia Clickject | None | 12 | $55,903 | $4,659 |
| Xeljanz Xr | None | 11 | $53,441 | $4,858 |
| Hydroxychloroquine Sulfate | None | 153 | $9,892 | $65 |
| Colcrys | None | 16 | $5,336 | $334 |
| Colchicine | None | 15 | $4,131 | $275 |
| Leflunomide | None | 28 | $2,937 | $105 |
| Febuxostat | None | 16 | $2,143 | $134 |
| Mycophenolate Mofetil | None | 27 | $2,137 | $79 |
| Methylprednisolone | None | 20 | $1,579 | $79 |
| Prednisone | None | 171 | $1,468 | $9 |
| Cevimeline | None | 11 | $1,464 | $133 |
| Methotrexate | None | 40 | $1,352 | $34 |
| Diclofenac | None | 42 | $1,212 | $29 |
| Leucovorin | None | 11 | $480 | $44 |
| Sulfasalazine | None | 13 | $215 | $17 |
| Methotrexate | None | 11 | $153 | $14 |
| Sulfasalazine Dr | None | 12 | $100 | $8 |
| Tramadol | None | 45 | $96 | $2 |
| Trazodone | None | 11 | $58 | $5 |
| Buspirone | None | 11 | $48 | $4 |
| Alendronate | None | 11 | $48 | $4 |
| Meloxicam | None | 14 | $27 | $2 |
| Amlodipine Besylate | None | 13 | $18 | $1 |
2019: 20 drugs
| Xeljanz | 22 | $98,008 | $4,455 |
| Cimzia | 13 | $79,921 | $6,148 |
| Actemra | 25 | $72,450 | $2,898 |
| Benlysta | 13 | $47,455 | $3,650 |
| Hydroxychloroquine Sulfate | 130 | $11,887 | $91 |
| Rasuvo | 11 | $5,485 | $499 |
| Methotrexate | 68 | $2,463 | $36 |
| Mycophenolate Mofetil | 32 | $2,444 | $76 |
| Colchicine | 22 | $2,191 | $100 |
| Prednisone | 165 | $1,377 | $8 |
| Methylprednisolone | 19 | $906 | $48 |
| Diclofenac | 23 | $649 | $28 |
| Leucovorin | 18 | $381 | $21 |
| Celecoxib | 11 | $351 | $32 |
| Ondansetron Odt | 11 | $258 | $23 |
| Nifedipine Er | 11 | $249 | $23 |
| Gabapentin | 13 | $235 | $18 |
| Meloxicam | 18 | $118 | $7 |
| Alendronate | 11 | $114 | $10 |
| Tramadol | 16 | $71 | $4 |
2018: 14 drugs
| Humira | 16 | $82,530 | $5,158 |
| Cimzia | 11 | $66,347 | $6,032 |
| Actemra | 11 | $41,293 | $3,754 |
| Hydroxychloroquine Sulfate | 140 | $16,878 | $121 |
| Colcrys | 18 | $3,729 | $207 |
| Methotrexate | 69 | $3,635 | $53 |
| Mycophenolate Mofetil | 11 | $3,009 | $274 |
| Leflunomide | 11 | $2,066 | $188 |
| Prednisone | 121 | $1,514 | $13 |
| Azathioprine | 21 | $764 | $36 |
| Leucovorin | 15 | $365 | $24 |
| Nifedipine Er | 16 | $364 | $23 |
| Tramadol | 20 | $225 | $11 |
| Meloxicam | 17 | $72 | $4 |
2017: 4 drugs
| Hydroxychloroquine Sulfate | 80 | $10,373 | $130 |
| Colchicine | 13 | $2,375 | $183 |
| Methotrexate | 39 | $2,276 | $58 |
| Prednisone | 31 | $419 | $14 |
2016: 6 drugs
| Hydroxychloroquine Sulfate | 75 | $8,487 | $113 |
| Colchicine | 16 | $3,763 | $235 |
| Methotrexate | 38 | $1,779 | $47 |
| Methylprednisolone | 14 | $1,426 | $102 |
| Prednisone | 31 | $291 | $9 |
| Naproxen | 13 | $96 | $7 |
2015: 6 drugs
| Humira | 12 | $49,910 | $4,159 |
| Hydroxychloroquine Sulfate | 75 | $11,100 | $148 |
| Colcrys | 12 | $3,657 | $305 |
| Methotrexate | 18 | $1,535 | $85 |
| Prednisone | 42 | $454 | $11 |
| Allopurinol | 16 | $101 | $6 |
2014: 3 drugs
| Methotrexate | 21 | $2,028 | $97 |
| Hydroxychloroquine Sulfate | 11 | $649 | $59 |
| Prednisone | 19 | $207 | $11 |
2013: 5 drugs
| Methotrexate | 30 | $1,848 | $62 |
| Hydroxychloroquine Sulfate | 31 | $628 | $20 |
| Omeprazole | 23 | $368 | $16 |
| Nifedipine Er | 11 | $310 | $28 |
| Prednisone | 14 | $80 | $6 |
Money from drug and device companies
$20 in 2024
A payment is not proof that care is biased.
| Dompe US | Oxervate | $20 | 1 payment
|
See the published payment
| Dompe US | Meals · 2024-07-23 | Oxervate | $20 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1427217223
- Licence
- CA A139485, MA 254892California A139485: Current · expires 2027-05-31
- Trained
- Tufts University School of Medicine, 2008
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RR0500X (207RR0500X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2008-06-06
- NPI last updated
- 2024-04-12
- NPI record certified
- 2024-04-12
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1000 Welch Rd, Palo Alto, CA, 94304